David Pernock's most recent trade in Eagle Pharmaceuticals Inc was a trade of 9,700 Common Stock done . Disclosure was reported to the exchange on Feb. 2, 2021.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Eagle Pharmaceuticals Inc | David Pernock | Pres & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 9,700 | 54,625 (0%) | 0% | 0 | Common Stock | |
Eagle Pharmaceuticals Inc | David Pernock | Pres & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.70 per share. | 23 Jan 2021 | 1,892 | 44,925 (0%) | 0% | 47.7 | 90,248 | Common Stock |
Eagle Pharmaceuticals Inc | David Pernock | Pres & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.97 per share. | 07 Jan 2021 | 906 | 46,817 (0%) | 0% | 51.0 | 46,179 | Common Stock |
Eagle Pharmaceuticals Inc | David Pernock | Pres & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.02 per share. | 05 Jan 2021 | 2,088 | 47,723 (0%) | 0% | 50.0 | 104,442 | Common Stock |